USFDA approval delays for respiratory products
Approval for Flovent 44 mcg and other respiratory ANDAs may be delayed, impacting Q4 US revenue expectations.
high · analyst_question
Glenmark Pharmaceuticals Limited — Q3 FY26
Glenmark delivered a strong Q3 with consolidated revenue of ₹3,962 crore, up 15.1% YoY, driven by broad-based growth across markets and currency tailwinds.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Currency depreciation impact on reported growth
While currency tailwinds boosted reported revenue, constant currency growth in Europe may be lower than reported 9.1%.
medium · analyst_questionGross margin pressure from product mix
Excluding outlicensing income, gross margin was ~65%, impacted by product and geographic mix; recovery depends on new product approvals.
medium · data_observationWorking capital normalization challenges
Despite progress, working capital days may face pressure from business growth and payment cycles in emerging markets.
low · management_commentary